Market News / Story
Editas Medicine cleared to start Phase 1/2 trial of EDIT-401 in Australia; ~90% LDL-C preclinical reduction
·
Editas Medicine received approval to initiate the Phase 1/2 Strive trial of EDIT-401 for heterozygous familial hypercholesterolemia and reported durable ~90% LDL-C reductions in preclinical studies. Key Highlights: Regulatory/ethics approval obtained in Australia to start the Phase 1/2 Strive trial of EDIT-401; CTN completed with TGA. New Zealand submission pending; if approved, patients in both countries can enroll across five selected sites. EDIT-401 is designed to…